BÁO CÁO Y HỌC: "A META-ANALYSIS OF CAG (CYTARABINE, ACLARUBICIN, G-CSF) REGIMEN FOR THE TREATMENT OF 1029 PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME" PPSX
Tìm thấy 10,000 tài liệu liên quan tới tiêu đề "BÁO CÁO Y HỌC: "A META-ANALYSIS OF CAG (CYTARABINE, ACLARUBICIN, G-CSF) REGIMEN FOR THE TREATMENT OF...":
FBW7, FBXW7) has recently emerged as a potent new potential tumor suppressor gene [1, 2]. The highly conserved protein consists of an NH2 terminal F-box and seven WD40 repeats in the COOH terminal region and acts as an adaptor protein providing substrate specificity for SCF (Skp–Cullin–F-box)[r]
12. Stuyver L, et al. Hepatitis C virus genotyping by means of 5'-UR/core line probe assays and molecular analysis of untypeable samples. Virus Res 1995, 38: 137-57. 13. Zheng X, et al. Direct comparison of hepatitis C virus genotypes tested by INNO-LiPA HCV II and TRUGENE HCV genotyping methods. J[r]
and severity of disease. Am J Gastroenterol 2001; 96:2957. 10. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. Hepatology 2002; 35:367. 11. Marchesini G, Brizi M,[r]
severe with occasional lymphoid aggregates (Figure 2) [4,11]. Actively proliferating bile ductiles are often seen. Risk factors for severe recurrent HCV include advanced donor age, HCV genotype 1, high HCV RNA levels before and after transplant, early histological recurrence of HCV, concomitant cyto[r]
Cirrhosis), is a multicenter study of the potential benefit of prolonged peginterferon therapy in mitigating the progression of fibrotic liver disease. [8] In this study, 391 of the 1045 patients enrolled into the initial “lead-in” phase had biopsy proven cirrhosis. Preliminary results show t[r]
immunosuppression on recurrent HCV [1,4]. However, this is extremely difficult to achieve in most patients. In the post-liver transplant setting the differential diagnosis of elevated liver chemistry tests is broad and includes acute cellular or chronic ductopenic rejection, bacterial or viral (CMV[r]
past decade. Where on one hand, this treatment has proven its effectiveness in ideal population; it has also identified some special populations by way of poor response or difficulties faced due to co morbid conditions. These special populations include patients with cirrhosis, non responders to pri[r]
4. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-1440. 5. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, Urushihar[r]
virus. In this study, HCVRNA was detected more frequently in patients with anti-HCV positive (90.7% of 130) than in patients with HBsAg/anti-HCV positive (65.2% of 69, p<0.001). 5. Antivirus Therapy Few data exist on treatment of double infection. Some preliminary studies [45,46] showed that[r]
treatment, but relapse occurs frequently once treatment is discontinued.[70] Other frequent extrahepatic manifestations found in patient with chronic HCV infection are membranoproliferative glomerulonephritis, porphyria cutaneous tarda, lichen planus, and vitiligo. There is also some data that sugge[r]
Kevin Robertson5, Robert Paul6, Cecilia Shikuma1, Victor Valcour1 1. Hawaii AIDS Clinical Research Program, University of Hawaii, Honolulu, HI, USA; 2. Armed Forces Research Inst. Med. Sciences, Bangkok, Thailand; 3. Phramongkutklao Hosp., Bangkok, Thailand; 4. Royal Thai Army Med. Dept., Bangkok, T[r]
antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther. 2003; 17: 259-65. 17. Miki I, Aoyama N, Sakai T, et al. Impact of clarithromycin resistence and CYP2C19 genetic[r]
there is data suggesting that obesity accelerating fibrosis. 6. Research Direction Although significant advances in therapeutic options have improved the outcome in the management of HCV infection, many challenges remain ahead. The proportion of chronic HCV not responding to the available drugs is f[r]
Figure 1 shows the hierarchical gene expression profile of 1 mM ethanol concentration treated HepG2 cells (group 1) and control cells (HepG2 cells without treatment; group 2) exposed for a 6 h period. Data are presented as a median of the signal obtained from the six different microarr[r]
cells efficiently is treating these cells with DNA damaging reagents thereby introducing acute DNA damage. However, the majority DNA damage reagents are not specific and can cause the similar extent of damage in both BRCA1 mutant and wild type cells. More recently it was shown that PARP-1 inhibitors[r]
. The PCR was con-ducted with initial denaturation at 95°C for 10 minutes, 30 cycles of denaturation at 95°C for 1 minute, an-nealing at 60°C for 1 minute, and extension at 72°C for 1 minute, and a final extension at 72°C for 5 minutes. The primers were F1: 5’-AGC CTC TCC TGA CTG TCA TCC-3’,[r]
by all nucleated cells and is secreted into the blood at a constant rate [1, 2]. Cys-C is freely filtered through the normal glomerular membrane and completely reabsorbed, followed by catabolization by the proximal tubular cells [1, 2]. The biological fates of Cys-C are favorable as an endoge[r]
been identified to date [2], but the real number is probably higher, since less than 50% of known and putative genes have an identified function. The asso-ciation between defects in DNA repair and cancer was established by Cleaver in 1968 [3], who showed that xeroderma pigmentosum (XP) is caused by[r]
highly significant association between the rare C allele and lower plasma HDL concentrations in female subjects. The effect remained significant after correcting for multiparametric testing according to Bonferoni and was seen only in subjects with a BMI below the median. In addition, the non-[r]